Larson Tina Marriott's Form 4 filing
Recursion Pharmaceuticals, Inc.RXRX · filed Feb 27, 2023
- Accession no.
- 0001209191-23-013329
- Filed
- Feb 27, 2023
- Trade date
- Feb 23, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $62.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Larson Tina MarriottCIK 0001856414 | Officer (President and COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2023 | Class A Common Stock | MOption exerciseAcquired | +8,000 | $1.06 | +$8,480 | 435,844 | Direct | |
| Feb 23, 2023 | Class A Common Stock | SSaleDisposed | −8,000 | $7.82F2 | −$62,560 | 427,844 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2023 | Class A Common Stock | MOption exerciseDisposed | −8,000 | $0.00 | $0 | 546,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.74 to $8.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.